Tu1739 – Efficacy and Safety of Ustekinumab Through Week 16 in Patients with Moderate to Severe Ulcerative Colitis Randomized to Ustekinumab: Results from the Unifi Induction Trial
Silvio Danese(IRCCS Ospedale San Raffaele), Gert A. Van Assche, Rupert W. Leong(The University of Sydney), Stephan R. Targan(Cedars-Sinai Medical Center), David Rowbotham(University of Auckland), Colleen Marano(Johnson & Johnson (United States)), James Izanec(Janssen (United States)), Hongyan Zhang(Tianjin University), Christopher D. O’Brien(Cedars-Sinai Medical Center), Philippe Szapary(Cedars-Sinai Medical Center), Jewel Johanns(Johnson & Johnson (United States)), Sheldon Sloan(Pfizer (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k